Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Beverly Hills, California 90211-1850, United States
Washington D.C., District of Columbia 20037, United States
Baltimore, Maryland 21231, United States
Las Vegas, Nevada 89135, United States
Buenos Aires, AR C1425AWC, Argentina
Westmead, New South Wales 2145, Australia
Nedlands, Western Australia 6009, Australia
Victoria, 3050, Australia
Kelowna, British Columbia V1Y 5L3, Canada
Hanover, D-30625, Germany
Via Del Pozzo 71, Modena 41100, Italy
Lodz, 93-509, Poland